Phase II study of 1st-line durvalumab and platinum–etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC)

Elizabeth Dudnik, Hovav Nechushtan, Ofer Rotem, Ekaterina Hanovich, Mira Wollner, Tatiana Boikaner, Niel Fridman, Jonathan Ofer, Merav A Ben-David, Daniel Reinhorn · 2026

Read Phase II study of 1st-line durvalumab and platinum–etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC) by Elizabeth Dudnik, Hovav Nechushtan, Ofer Rotem, Ekaterina Hanovich, Mira Wollner, Tatiana Boikaner, Niel Fridman, Jonathan Ofer, Merav A Ben-David, Daniel Reinhorn (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13578167.txt.

Description

Elizabeth Dudnik leads a 2026 phase II trial of first-line chemo-immunotherapy for advanced large-cell neuroendocrine lung carcinoma, a rare and aggressive cancer with little trial data. Patients received durvalumab, an immune therapy, plus platinum and etoposide chemotherapy for four cycles, then durvalumab alone on a monthly schedule. The main goal was the share of patients free of progression at twelve months.

The trial closed early for slow recruitment after twelve of twenty-two planned patients joined. Median time without progression was 4.4 months, while the twelve-month progression-free share reached 25.0 percent, above the bar the design set. Half the patients' tumours shrank measurably, and all three patients with untreated brain spread saw it clear completely inside the skull. Side effects were mostly mild, with no treatment-related deaths. The authors call the results consistent with their hopes, while stressing the small numbers.

Catalog record

CREATORElizabeth Dudnik, Hovav Nechushtan, Ofer Rotem, Ekaterina Hanovich, Mira Wollner, Tatiana Boikaner, Niel Fridman, Jonathan Ofer, Merav A Ben-David, Daniel Reinhorn
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41852
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13578167

Browse the full library · About the Tower of Babel